D&O

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Retrieved on: 
Tuesday, March 26, 2024
Research, AXL, Head, Congress, NSCLC, SAN, Patient, Webcast, Observation, G&A, Peripheral neuropathy, CAB, Melanoma, D&O, Sarcoma, CD3, AACR, DLT, Conditional, ESMO, SITC, Therapy, ADC, Annual general meeting, SCCHN, Pharmaceutical industry

General and administrative (G&A) expenses were $5.9 million for the quarter ended December 31, 2023 compared to $6.7 million for the same quarter in 2022.

Key Points: 
  • General and administrative (G&A) expenses were $5.9 million for the quarter ended December 31, 2023 compared to $6.7 million for the same quarter in 2022.
  • Net loss for the quarter ended December 31, 2023 was $26.9 million compared to a net loss of $27.6 million for the same quarter in 2022.
  • Cash used for the quarter ended December 31, 2023 was $29.8 million.
  • Cash and cash equivalents as of December 31, 2023 were $111.5 million, compared to $215.5 million as of December 31, 2022.

ParaZero Announces 2023 Financial Results

Retrieved on: 
Friday, March 22, 2024
Research, Environment, Growth, EASA, Nitrox, Partnership, Black Square, Travel, IPO, Insurance, D&O, OEM, European, Safety, KULR, Marketing, TEL

TEL AVIV, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the "company” or “ParaZero”), an aerospace company focused on drone technologies for commercial drones, defense drones, and urban air mobility aircraft, reported today its financial results for year ended December 31, 2023.

Key Points: 
  • TEL AVIV, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the "company” or “ParaZero”), an aerospace company focused on drone technologies for commercial drones, defense drones, and urban air mobility aircraft, reported today its financial results for year ended December 31, 2023.
  • ParaZero closed its IPO on July 31, 2023, issuing 1,950,000 ordinary shares.
  • ParaZero's CEO, Boaz Shetzer, stated, "2023 was a crucial year for ParaZero, as we continued to push the boundaries of innovation in drone safety.
  • Full Year 2023 Financial Highlights:
    Sales increased by $60,390, or 10.8% to $620,508 for the year ended December 31, 2023, compared to $560,118 for the year ended December 31, 2022.

Health and safety emerges as top risk facing global directors according to WTW’s and Clyde & Co’s latest survey

Retrieved on: 
Wednesday, March 20, 2024
Transfer, Health, Crime, Climate change, Risk management, Alternative risk transfer, Risk, Education, Mental health, Clyde & Co, D&O, WTW, Safety, Occupational safety and health

LONDON, March 20, 2024 (GLOBE NEWSWIRE) -- Health & safety emerges as the top risk for directors and officers according to the 2024 Global Directors’ and Officers’ Survey Report from WTW (NASDAQ: WTW), a leading global advisory, broking, and solutions company, and Clyde & Co, a leading global law firm.

Key Points: 
  • LONDON, March 20, 2024 (GLOBE NEWSWIRE) -- Health & safety emerges as the top risk for directors and officers according to the 2024 Global Directors’ and Officers’ Survey Report from WTW (NASDAQ: WTW), a leading global advisory, broking, and solutions company, and Clyde & Co, a leading global law firm.
  • Overall, health and safety was considered the top risk with 84% of global directors, officers and risk managers ranking it as very or extremely important, closely followed by cyber-attack (including cyber extortion) risks on 79%.
  • Jeremy Wall, Head of Global FINEX, WTW, said: “We are pleased to be launching the 2024 Global Directors’ and Officers’ Survey Report in collaboration with Clyde & Co.
  • “While the last five years have seen cyber and data breaches being a top risk for directors and officers, it was a surprise to see Health & Safety be considered the top risk.

Lifeist Announces Results of Annual General and Special Meeting of Shareholders

Retrieved on: 
Wednesday, March 20, 2024
Remuneration, Science, Proxy, Sale, Public sector, Insurance, D&O, Drink, AGSM, Special, Mikra, Management

TORONTO, March 20, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, today announced the results of the Company’s Annual General and Special Meeting of the shareholders held on March 14, 2024 (the “AGSM”).

Key Points: 
  • TORONTO, March 20, 2024 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, today announced the results of the Company’s Annual General and Special Meeting of the shareholders held on March 14, 2024 (the “AGSM”).
  • Clearhouse LLP, Chartered Public Accountants were appointed as the Company's auditor to hold office until the next annual meeting of shareholders or until its successor is duly appointed, at a remuneration to be fixed by the Board.
  • The special resolution for the proposed sale of the Company’s CannMart Group did not meet a super majority and therefore was not approved.
  • The proposed sale of the CannMart Group was intended to divest Lifeist of the continued negative cash flow that the cannabis business has cost shareholders since inception.

IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, March 14, 2024
MGMT, Research, Survival, ASH, CD33, Environment, Patient, GBM, Neoplasm, Temozolomide, D&O, IND, AACR, Glioblastoma, Exposition, Research and development, Society, CD123, PFS, Cell, DRI, Cranial cavity, Pharmaceutical industry

(Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.

Key Points: 
  • (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today reported financial results and business highlights for the fourth quarter and full-year ended December 31, 2023.
  • “IN8bio entered 2024 with significant momentum behind the company,” said William Ho, CEO and co-founder of IN8bio.
  • “Despite the difficult environment in 2023, the IN8bio team executed operationally and successfully advanced our programs.
  • Cash position: As of December 31, 2023, the Company had cash of $21.3 million, compared to $18.2 million as of December 31, 2022.

Oasis Announces Third Year of Support for Japanese Women to Receive Director Training, in Cooperation with BDTI of Japan

Retrieved on: 
Monday, April 1, 2024
Professional Services, Education, Business, Consumer, Women, Training, Initiative, Q&A, Case study, CFO, Oasis, ESG, Strategic planning, Female, Interview, D&O, Financial regulation, Bank statement, Woman, Boot camp, P&L, Corporate law, CFA, Person, CCC, CPA, Nursing

For the third year in a row, Oasis Management Company Ltd. (“Oasis”) will support director training for women in Japan at the Board Director Training Institute of Japan (“BDTI”).

Key Points: 
  • For the third year in a row, Oasis Management Company Ltd. (“Oasis”) will support director training for women in Japan at the Board Director Training Institute of Japan (“BDTI”).
  • Oasis will pay all costs for qualified women who enroll by the end of June to take any of BDTI’s director training courses described below.
  • BDTI Representative Director Nicholas Benes said, “In previous years, so many qualified women applied that we scheduled additional dates for more programs.
  • BDTI also packages its e-learning modules with this course, for Japanese speakers.

Ellomay Capital Reports Results for the Fourth Quarter and Full Year of 2023

Retrieved on: 
Sunday, March 31, 2024
Shekel, Season, Tax, Agreement, Dorad Power Station, SWAP, Sale, P-50, Depreciation, Disclosure, Bank statement, RDL, Electricity, Klahim, Legislation, AMPA, Iron, Public expenditure, Good, Israeli new shekel, PPA, Zorlu, Komemiyut, Bank Mizrahi-Tefahot, Acquisition, PV, EBIDTA, Loss, D&O, Greenhouse, Government, Total, Renewable energy

•  Operating expenses were approximately €22.9 million for the year ended December 31, 2023, compared to approximately €23.7 million for the year ended December 31, 2022.

Key Points: 
  • •  Operating expenses were approximately €22.9 million for the year ended December 31, 2023, compared to approximately €23.7 million for the year ended December 31, 2022.
  • •  Project development costs were approximately €4.5 million for the year ended December 31, 2023, compared to approximately €3.8 million for the year ended December 31, 2022.
  • During 2023, the Ellomay Solar project (28 MW) produced revenues from the sale of electricity and green certificates of approximately €4 million.
  • The Company's EBITDA may not be indicative of the Company's historic operating results; nor is it meant to be predictive of potential future results.

Inspira™ Technologies Reports Full Year 2023 Financial Results

Retrieved on: 
Monday, March 25, 2024
ART, OXY, Research, Annual report, Unitary state, IIA, Intubation, Risk, Patent, Patient, Coma, S&M, Hospital, G&A, Coagulation, Insurance, D&O, Carbon, Human, Hemolysis, Marketing, FDA, Total, Food, Pharmaceutical industry

RA'ANANA, Israel, March 25, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, today announced its financial results for the year ended December 31, 2023.

Key Points: 
  • Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a breakthrough medical technology company, today announced its financial results for the year ended December 31, 2023.
  • With our ground-breaking technologies and products, we are not just looking at the horizon but actively shaping it, leveraging our proprietary technologies to make a meaningful impact."
  • Total operating expenses decreased to US$12,133,000 in of the year ended December 31, 2023, from US$14,893,000 in the same period of 2022.
  • As of December 31, 2023, financial liabilities at fair value totaled US$1,470,000 compared to US$26,000.

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, March 8, 2024
OXM, Woman, Injection, Research, Bone fracture, Clinical research associate, Type D, FDA, BMD, PTH, Food, Hypoparathyroidism, Obesity, Coeliac disease, Weight loss, Oxyntomodulin, Cmax, Elective surgery, Sport, Short bowel syndrome, OPKO Health, DSM-IV codes, Ecosystem, SABRE, Patient, D&O, Intellectual property, Fracture, Athlete, Sports medicine, Tablet, Osteoporosis, Insurance

JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.
  • Following our December 2023 financing, we expect to have sufficient cash to fund operations through the first half of 2025,” said Miranda Toledano, CEO of Entera.
  • Financial Results for the year Ended December 31, 2023
    As of December 31, 2023, Entera had cash and cash equivalents of $11.0 million.
  • Operating expenses for year ended December 31, 2023 were $8.9 million, as compared to $13.0 million for the year ended December 31, 2022.

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 7, 2024
Head, Restart, Neoplasm, Food, Government, Safety, Lawrence, Massachusetts, PMDA, Patient, Carcinoma, D&O, Brain, Lung cancer, Clinical trial, Alpha, G&A, Radiation, Pancreatic cancer, Liver disease, Pharmaceutical industry

We are also exploring the addition of new clinical trials in the U.S., based upon recent positive regulatory feedback.

Key Points: 
  • We are also exploring the addition of new clinical trials in the U.S., based upon recent positive regulatory feedback.
  • The Alpha DaRT procedure was deemed technically successful in all five cases, with Alpha DaRT sources successfully inserted into the target tumors.
  • Targeting completion of patient recruitment in the ReSTART pivotal U.S. multi-center trial in recurrent cutaneous squamous cell carcinoma in H2 2024.
  • The Company expects that this cash balance will be sufficient to fund operations for at least two years.